Cost-Effectiveness of Voclosporin in Combination with Mycophenolate Mofetil for Active Lupus Nephritis in Sweden (ISPOR-EU 2023) - Oct 4, 2023 - Abstract #EE272; Pres time: Nov 13, 2023; 03:30 PM - 06:30 PM; P3 | "Based on a willingness-to-pay threshold of 750,000 SEK, VCS+MMF is considered a cost-effective treatment compared to MMF for adults with lupus nephritis in Sweden."
Combination therapy • Cost effectiveness • HEOR • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Transplantation
|
|
Gittfried A1; Farrington E2; Anell B3; Norman H4; Clamp D2; Blaikie T5; Ektare V6
|